Table 4. Hazard ratios of clinical characteristics associated with overall mortality in the overall patient population.
| Univariate model | HR (95% CI) | P value |
|---|---|---|
| Age, per 1 year | 0.99 (0.98-1.00) | 0.031 |
| Sex, male | 0.89 (0.65-1.22) | 0.46 |
| Etiology | 0.87 | |
| Hepatitis B virus | 1.17 (0.67-2.05) | 0.58 |
| Hepatitis C virus | 0.84 (0.31-2.26) | 0.73 |
| Others or unknown | 0.90 (0.58-1.39) | 0.62 |
| Child-Pugh stage, B | 2.05 (1.54-2.72) | <0.001 |
| AFP ≥ 400 ng/mL | 1.46 (1.14-1.86) | 0.002 |
| ECOG performance status, 1 | 1.65 (1.30-2.11) | <0.001 |
| Duration of sorafenib treatment, per 1 week | 0.98 (0.97-0.98) | <0.001 |
| TACE procedure during the study period | 0.95 (0.75-1.21) | 0.70 |
| Presence of portal vein invasion | 1.19 (0.94-1.50) | 0.16 |
| Radiation therapy for portal vein invasion | 0.71 (0.48-1.04) | 0.08 |
| Presence of distant metastasis | 0.90 (0.68-1.19) | 0.44 |
| Multivariate model | OR (95% CI) | P value |
| Age, per 1 year | 0.99 (0.97-1.02) | 0.56 |
| Child-Pugh stage, B | 1.65 (1.06-2.55) | 0.026 |
| AFP ≥ 400 ng/mL | 1.01 (0.65-1.57) | 0.98 |
| ECOG performance status, 1 | 1.32 (0.88-1.99) | 0.18 |
| Duration of sorafenib treatment, per 1 week | 0.97 (0.95-0.99) | <0.001 |
| Radiation therapy for portal vein invasion | 0.68 (0.44-1.04) | 0.07 |
HR, hazard ratio; CI, confidence interval; AFP, alpha fetoprotein; ECOG, Eastern Cooperative Oncology Group; TACE, transarterial chemoembolization